fluorouracil has been researched along with Gasser Syndrome in 15 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A patient receiving the antitumor agent mitomycin C (MMC) in combination with 5-fluorouracil and adriamycin because of adenocarcinoma of Vater's papilla manifested hemolytic-uremic syndrome (HUS) after five cycles of 5-fluorouracil-adriamycin-MMC combination chemotherapy." | 8.77 | Carcinoma-associated hemolytic-uremic syndrome in a patient receiving 5-fluorouracil-adriamycin-mitomycin C combination chemotherapy. ( Binsack, T; Mergenthaler, HG; Wilmanns, W, 1988) |
| " Until ongoing phase III trials confirm these benefits, the current standard treatment for metastatic pancreatic adenocarcinoma remains single agent gemcitabine." | 4.81 | A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma. ( Bruckner, HW; Kozuch, P; Petryk, M, 2002) |
| "A patient receiving the antitumor agent mitomycin C (MMC) in combination with 5-fluorouracil and adriamycin because of adenocarcinoma of Vater's papilla manifested hemolytic-uremic syndrome (HUS) after five cycles of 5-fluorouracil-adriamycin-MMC combination chemotherapy." | 4.77 | Carcinoma-associated hemolytic-uremic syndrome in a patient receiving 5-fluorouracil-adriamycin-mitomycin C combination chemotherapy. ( Binsack, T; Mergenthaler, HG; Wilmanns, W, 1988) |
| " We describe two patients with breast cancer in remission after treatment with mitomycin in combination with 5-fluorouracil." | 3.69 | [Chemotherapy-induced hemolytic uremic syndrome. A complication to mitomycin treatment of breast carcinoma]. ( Hagen, T; Jakobsen, E; Ottestad, L; Schjølseth, SA, 1995) |
| "A 63-year-old male had undergone combination chemotherapy including adriamycin, cisplatin, mitomycin C, 5-fluorouracil and vindesine for six months for double cancer of esophagus and stomach." | 3.68 | [Chemotherapy-associated hemolytic uremic syndrome--a case report]. ( Kanamaru, R; Kikuchi, H, 1992) |
| "In this large pooled analysis, we found MMC, when capped at a cumulative dose of 36 mg/m(2), to be safe and tolerable in combination with capecitabine or irinotecan with no reportable cases of TTP/HUS." | 2.46 | Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials. ( Arce-Lara, C; Bekaii-Saab, T; Cataland, S; Kraut, E; Ntukidem, N; Otterson, GA, 2010) |
| " The case history reported here is discussed in relation to dose and scheduling of mitomycin C, and a safe maximum dosage is suggested." | 1.28 | Cancer-associated hemolytic-uremic syndrome with spontaneous resolution. A case report. ( Abdolrahimzadeh, S; Barone, C; Franchi, F; Gozzer, M; Seminara, P, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (40.00) | 18.7374 |
| 1990's | 4 (26.67) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahlgren, J | 1 |
| Patel, N | 1 |
| Simmens, S | 1 |
| Akin, E | 1 |
| Bishop, C | 1 |
| Kirkel, D | 1 |
| Siegel, P | 1 |
| Schuck, S | 1 |
| Guebre-Xabiher, H | 1 |
| Siegel, R | 1 |
| Ntukidem, N | 1 |
| Arce-Lara, C | 1 |
| Otterson, GA | 1 |
| Kraut, E | 1 |
| Cataland, S | 1 |
| Bekaii-Saab, T | 1 |
| Hofheinz, RD | 1 |
| Hartung, G | 1 |
| Samel, S | 1 |
| Hochhaus, A | 1 |
| Pichlmeier, U | 1 |
| Post, S | 1 |
| Hehlmann, R | 1 |
| Queisser, W | 1 |
| Steffens, F | 1 |
| Willie, GR | 1 |
| Levy, SM | 1 |
| Michaels, RS | 1 |
| Zirkin, RM | 1 |
| Crocker, J | 1 |
| Jones, EL | 1 |
| Schjølseth, SA | 1 |
| Hagen, T | 1 |
| Ottestad, L | 1 |
| Jakobsen, E | 1 |
| Tohda, S | 1 |
| Shiigai, T | 1 |
| Jibiki, M | 1 |
| Aoi, T | 1 |
| Ueda, Y | 1 |
| Kawasaki, T | 1 |
| Kurokawa, H | 1 |
| Nara, N | 1 |
| Kozuch, P | 1 |
| Petryk, M | 1 |
| Bruckner, HW | 1 |
| Kikuchi, H | 1 |
| Kanamaru, R | 1 |
| Seminara, P | 1 |
| Franchi, F | 1 |
| Abdolrahimzadeh, S | 1 |
| Gozzer, M | 1 |
| Barone, C | 1 |
| Jain, S | 1 |
| Seymour, AE | 1 |
| Mergenthaler, HG | 1 |
| Binsack, T | 1 |
| Wilmanns, W | 1 |
| de Insausti, CL | 1 |
| Gutiérrez, LE | 1 |
| van der Gaast, A | 1 |
| Verweij, J | 1 |
| Planting, AS | 1 |
| Stoter, G | 1 |
3 reviews available for fluorouracil and Gasser Syndrome
| Article | Year |
|---|---|
Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic | 2010 |
A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow D | 2002 |
Carcinoma-associated hemolytic-uremic syndrome in a patient receiving 5-fluorouracil-adriamycin-mitomycin C combination chemotherapy.
Topics: Adenocarcinoma; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasm | 1988 |
1 trial available for fluorouracil and Gasser Syndrome
| Article | Year |
|---|---|
High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer. A phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Do | 2002 |
11 other studies available for fluorouracil and Gasser Syndrome
| Article | Year |
|---|---|
O-MAX chemotherapy: high activity in metastatic esophagogastric adenocarcinoma and possible relation to subclinical hemolysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2014 |
[Mitomycin-induced hemolytic uremia syndrome].
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Do | 2004 |
Hemolytic-uremic syndrome in a patient receiving mitomycin C and 5-fluorouracil.
Topics: Adenocarcinoma, Mucinous; Aged; Colonic Neoplasms; Fluorouracil; Hemolytic-Uremic Syndrome; Humans; | 1983 |
Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Drug Therapy, Combination; Female; Fluorouracil; Hemolytic | 1983 |
[Chemotherapy-induced hemolytic uremic syndrome. A complication to mitomycin treatment of breast carcinoma].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 1995 |
[Three cases of drug-induced hemolytic uremic syndrome].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Fluorouracil; Gastrointest | 1996 |
[Chemotherapy-associated hemolytic uremic syndrome--a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1992 |
Cancer-associated hemolytic-uremic syndrome with spontaneous resolution. A case report.
Topics: Antineoplastic Agents; Female; Fluorouracil; Hemolytic-Uremic Syndrome; Humans; Middle Aged; Mitomyc | 1991 |
Mitomycin C associated hemolytic uremic syndrome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Doxorubicin; Fluorouracil; Hemolyti | 1987 |
[Hemolytic-uremic syndrome caused by mitomycin C].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Hemolytic-Uremic Syndr | 1988 |
5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evalu | 1988 |